Previous close | 0.1704 |
Open | 0.1800 |
Bid | 0.1521 x 900 |
Ask | 0.1799 x 1400 |
Day's range | 0.1700 - 0.1860 |
52-week range | 0.1240 - 3.9500 |
Volume | |
Avg. volume | 6,471,604 |
Market cap | 9.667M |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.7200 |
Earnings date | 13 Nov 2020 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RICHMOND, Va., July 08, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseas
RICHMOND, Va., April 14, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC ("Guthy-Renker"). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to work
RICHMOND, Va., April 05, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company’s $14.5 million loan, plus interest to Cellvera Global Holdings LLC ("Cellvera"), formerly AiPharma Global Holdings LLC. The Company has signed the agreement as consideration for Aditxt’s separa